Special Issue

Peptide-Based Drugs for Cancer Therapies

Message from the Guest Editors

Occupying the sweet middle space between small organic molecules and large proteins, peptides have demonstrated several unique advantages as potential drug candidates, including low toxicity, low immunogenicity, high potency and specificity. Moreover, technological developments toward peptide synthesis have improved the feasibility of peptide drug development. Thus, peptide therapeutics represent strong candidates for the growth and innovation of the future pharmaceutical world. In fact, the estimated global revenue of peptide therapeutics is expected to reach USD 50.60 billion by the year 2026. The latest survey of peptide-based drugs shows that more than 80 peptide-based drugs have been approved on the global market up until 2021, with another 155 peptides in various stages of clinical development and 400-600 more in preclinical stages. Notably, employing peptides in cancer treatment and management is one of the most topical directions in drug development. The aim of this Special Issue on "Peptide-Based Drugs for Cancer **Therapies**" is to emphasize current research efforts towards the development of novel peptide-based therapeutics for oncology.

Guest Editors

Dr. Iman Kavianinia

School of Biological Sciences, Maurice Wilkins Centre for Molecular Biodiscovery, University of Auckland, Auckland 1010, New Zealand

Dr. Makhdoom Sarwar

Department of Obstetrics & Gynaecology, School of Medicine, University of Otago, Christchurch 8140, New Zealand

Deadline for manuscript submissions

closed (10 May 2023)



Pharmaceutics

an Open Access Journal by MDPI

Impact Factor 5.5 CiteScore 10.0 Indexed in PubMed



mdpi.com/si/90657

Pharmaceutics
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
pharmaceutics@mdpi.com

mdpi.com/journal/pharmaceutics





an Open Access Journal by MDPI

Impact Factor 5.5 CiteScore 10.0 Indexed in PubMed



About the Journal

Message from the Editor-in-Chief

Pharmaceutics (ISSN 1999-4923) is an online open access journal on the science and technology of pharmaceutics and biopharmaceutics. The scientific community, the wider community and the general public have unlimited and free access to the content as soon as a paper is published; this open access to your research ensures your findings are shared with the widest possible audience. Please consider publishing your impressive work in this high quality journal. We would be pleased to welcome you as one of our authors.

Editor-in-Chief

Prof. Dr. Patrick J. Sinko

Ernest Mario School of Pharmacy, Rutgers, The State University of New Jersey, William Levine Hall, Room 225C, 160 Frelinghuysen Road, Piscataway, NJ 08854-8020, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmaceutical Science)

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 14.9 days after submission; acceptance to publication is undertaken in 3.3 days (median values for papers published in this journal in the first half of 2025).

